Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical holding and development company that acquires, licenses, and advances drug assets through a network of subsidiaries and partner companies. Its model combines product revenue from commercial assets with royalty, equity, and financing-related income, while using Fortress’s scientific, regulatory, legal, and capital-markets capabilities to support development and monetization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMarketed pharmaceutical products sold primarily through Journey Medical, including dermatology therapies.
Drug candidates and programs held in Fortress subsidiaries that require clinical, regulatory, and partnering support.
Upfront, milestone, and termination-related proceeds from licensing and strategic transactions.
Income and value creation from ownership stakes, royalties, and dividends in partner companies.
Tuotteet
Raportoitu · osuus liikevaihdosta- Qbrexza40,8 %
- Emrosi24,1 %
- Accutane21,0 %
- Foam Franchise Products9,6 %
- Other Legacy Product Revenue4,5 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Fortress’s direct paying customers are mainly physicians, pharmacies, and healthcare channels that purchase Journey Medical’s marketed dermatology products. Indirectly, the company also serves pharmaceutical partners, universities, and research institutions that license assets, co-develop programs, or enter strategic transactions with Fortress and its subsidiaries. The business depends on both commercial end-markets and counterparties willing to fund or acquire development assets.
They buy Journey Medical's marketed products for acne, rosacea, and related skin conditions because the therapies are already commercialized and reimbursable.
They license, acquire, or co-develop Fortress-originated assets to gain access to programs with clinical or commercial potential.
They do not buy directly, but they determine formulary access and pricing economics for commercial products.
They contribute intellectual property and early-stage assets that Fortress can acquire or license for development.
They provide capital through public or private financings that support subsidiary development and commercialization.
Strategia
Fortress’s strategy is to acquire or license promising drug assets, advance them through subsidiaries, and monetize them through commercialization, partnering, or sale. It also seeks to preserve optionality by using equity stakes, royalties, and transaction proceeds to fund development without relying solely on internal cash generation. Recent disclosures show continued emphasis on portfolio management, including deconsolidation or sale of assets when value can be realized.
The company’s value creation depends on moving selected programs toward approval, commercialization, or strategic sale.
Development-stage biotech requires ongoing capital, and Fortress uses multiple funding sources to reduce dependence on one channel.
Commercial product revenue is the main operating cash source and helps offset development spending.
Maantiede
Fortress is headquartered in the United States and its business is primarily U.S.-centric, with commercial revenue largely tied to domestic product sales. The company also has selective international exposure through licensing, supply, and partnering transactions, such as the Cutia and AnnJi-related revenue items disclosed in the quarter. Geography matters mainly through regulatory jurisdiction, reimbursement dynamics, and the location of counterparties rather than a broad manufacturing footprint.
Riskit
Fortress faces the classic risks of a biotech platform: clinical failure, regulatory setbacks, and dependence on third-party manufacturing and commercialization partners. Its holding-company structure adds financing, integration, and transaction-execution risk, while commercial products remain exposed to generic competition, reimbursement pressure, and sales-force disruption. Because value is spread across subsidiaries and partner companies, adverse events at one asset can affect Fortress’s equity value and cash flows.
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Development and operating needs may require additional equity or debt capital if cash generation is insufficient.
Kohdistuu: Fortress and funded subsidiaries
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Most product candidates are early-stage and may not advance successfully through trials or approval.
Kohdistuu: Pipeline assets across Fortress subsidiaries
- Generic competition and pricing erosionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercial products can lose exclusivity and face intense price pressure from generics and payor substitution.
Kohdistuu: Journey Medical marketed products
- Commercial execution dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Revenue depends on maintaining Journey's sales force and third-party commercialization arrangements.
Kohdistuu: Journey Medical
- Cybersecurity and data integrityVaikutus: KeskitasoTodennäköisyys: Matala
Clinical, IP, and confidential data are stored and transmitted across internal and third-party systems.
Kohdistuu: R&D and outsourced operations
Kirjanpito
Harkinnanvaraiset erätProduct sales, supply arrangements, and license/termination proceeds are recognized differently and can distort comparability across periods.
Vaikutus: Quarterly revenue mix and margins
Selling or losing control of subsidiaries changes reported revenue, expenses, and balance sheet presentation.
Vaikutus: Checkpoint deconsolidation reduced reported operating items
Holdings in partner companies and warrant liabilities can create gains or losses unrelated to operations.
Vaikutus: Other income/expense volatility
Acquired drug assets and related intangibles may need impairment if programs underperform or are sold.
Vaikutus: Potential non-cash charges
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Forte Biosciences, Inc.
Pharmaceutical Preparations
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Fort Technology Inc
FRTT · Agricultural Chemicals
Fort Technology Inc is a consumer products company focused on pest control and remedial repair goods sold under proprietary brands such as Roshield, Entopest, Rempro and BirdGo.
Celularity Inc
CELU · Pharmaceutical Preparations
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026